Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) Stock Statistics & Valuation Metrics

Xuanzhu Biopharmaceutical Co., Ltd. Class H has a market cap or net worth of HK$6.90B. The enterprise value is HK$8.25B.

Xuanzhu Biopharmaceutical Co., Ltd. Class H has 160,702,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xuanzhu Biopharmaceutical Co., Ltd. Class H’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -16.01%.

The current PE Ratio of Xuanzhu Biopharmaceutical Co., Ltd. Class H is ―. Xuanzhu Biopharmaceutical Co., Ltd. Class H’s PEG ratio is 2.47.

In the last 12 months, Xuanzhu Biopharmaceutical Co., Ltd. Class H had revenue of 56.15M and earned -266.26M in profits. Earnings per share was -0.51.

In the last 12 months, operating cash flow was -70.01M and capital expenditures -2.13K, giving a free cash flow of -70.02M billion.

Xuanzhu Biopharmaceutical Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Xuanzhu Biopharmaceutical Co., Ltd. Class H upcoming earnings date is Mar 30, 2026, Before Open (Confirmed).

Xuanzhu Biopharmaceutical Co., Ltd. Class H as a current ratio of 3.75, with Debt / Equity ratio of 0.05%

In the past 12 months, Xuanzhu Biopharmaceutical Co., Ltd. Class H has paid 6.51K in taxes.

Xuanzhu Biopharmaceutical Co., Ltd. Class H EV to EBITDA ratio is -162.10, with an EV/FCF ratio of -159.89.

Xuanzhu Biopharmaceutical Co., Ltd. Class H has HK$216.62M in cash and marketable securities with HK$1.37M in debt, giving a net cash position of HK$215.26M billion.

Gross margin is 38.82%, with operating margin of -450.85%, and net profit margin of -474.21%.

The average price target for Xuanzhu Biopharmaceutical Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―